Furaline 4.5 To 10Kg Dog Tablet

Veko Furaline 250mg is a standout product in our FLEA, TICK & MITE CONTROL category. Manufactured with utmost pharmaceutical precision by Veko Care Pvt. Ltd. one of India's most trusted and respected veterinary pharmaceutical companies, operating from their own WHO-GMP and Australia-GMP approved manufacturing facility in Pune Furaline is India's leading generic equivalent of the globally recognised Bravecto brand, delivering the same active ingredient (Fluralaner) at the same therapeutic dose concentration with the same proven clinical efficacy at a significantly more accessible price point for Indian pet owners. Fluralaner is a member of the isoxazoline class of antiparasitic compounds the most advanced generation of systemic ectoparasiticides currently available in veterinary medicine which acts through a completely novel mechanism of action that is entirely distinct from all older antiparasitic classes, making it effective even against populations of fleas and ticks that have developed resistance to pyrethroids, organophosphates, and other conventional ectoparasiticides. The 250mg strength is precisely calibrated for dogs weighing 4.5 to 10kg delivering the exact therapeutic Fluralaner concentration of 25–56mg/kg body weight required for complete and sustained ectoparasitic coverage throughout the full 12-week treatment interval. Each Furaline tablet is a protein-flavoured "Yum-Tab" that most dogs accept voluntarily as a treat eliminating the stress, struggle, and topical product residue that make conventional spot-on, spray, and collar-based flea and tick treatments so challenging for small breed dog owners. With Veko Furaline, you can trust that you are offering your beloved furry companion the most advanced, most convenient, and most comprehensively protective oral ectoparasiticide available in India.

Composition:

• Fluralaner 250mg (Active Ingredient Isoxazoline Class): a novel, highly potent systemic insecticide and acaricide belonging to the isoxazoline chemical class the most recently developed and most pharmacologically advanced generation of ectoparasiticides in veterinary medicine. Following oral administration, Fluralaner is rapidly absorbed from the gastrointestinal tract, enters the systemic circulation, and is distributed throughout the body including the skin and subcutaneous tissues where it achieves and maintains therapeutic concentrations for a full 12 weeks after a single dose. The mechanism of action is highly selective and completely novel: Fluralaner acts as a potent antagonist at GABA-gated chloride ion channels and glutamate-gated chloride channels in arthropod nerve cells. In ectoparasites (fleas, ticks, mites, lice), these chloride channels are the primary mediators of neurological inhibition blocking their function causes uncontrolled, sustained nerve cell excitation, leading to hyperexcitability, uncoordinated muscular activity, paralysis, and rapid death of the parasite. The critical safety advantage of Fluralaner's isoxazoline mechanism is the profound difference in pharmacological selectivity between arthropod and mammalian GABA receptors mammalian GABA receptors have a fundamentally different subunit composition and binding pharmacology that makes them significantly less sensitive to Fluralaner at the therapeutic concentrations achieved in a treated dog's plasma, providing a favourable safety margin in dogs when used at the recommended dose. Fluralaner's exceptionally long plasma half-life in dogs approximately 12 to 15 days combined with its sustained distribution into skin and subcutaneous fat provides the unique 12-week ectoparasiticide persistence that is Furaline's defining clinical advantage over all conventional monthly or weekly ectoparasiticides
• Protein-Flavoured Palatable Chewable Tablet Base (Yum-Tab Technology): a proprietary chewable tablet matrix incorporating high-palatability protein-based flavouring that creates a tablet virtually indistinguishable from a treat in terms of taste, aroma, and texture ensuring voluntary acceptance by the vast majority of dogs without the need for food hiding, forced administration, or behavioural conditioning. The chewable texture allows complete tablet consumption without swallowing concerns and facilitates rapid gastrointestinal absorption of the active ingredient